One step back: Why the new Alzheimer's plaque-attack drugs don't work
On Jan. 31, aducanumab, a pricey drug approved for treatment of early-stage Alzheimer's disease, was withdrawn from the market. And in early March, the Food and Drug Administration delayed its decision regarding whether to ...
Mar 14, 2024
0
0